Antiprotozoal Lysophospholipid Analogues: A Comparison of their Activity Against Trypanosomatid Parasites and Tumor Cells
Tipo de material:
TextoSeries ; Mini-Reviews in Medicinal Chemistry, 4(2), p.141-151, 2004Trabajos contenidos: - De Castro, S.L
- Santa-Rita, R.M
- Urbina, J.A
- Croft, S.L
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
Documentos solicitados
|
CICY Documento préstamo interbibliotecario | Ref1 | B-11072 (Browse shelf(Opens below)) | Available |
Browsing CICY shelves, Shelving location: Documento préstamo interbibliotecario, Collection: Ref1 Close shelf browser (Hides shelf browser)
Lysophospholipid analogues (LPAs), originally developed as anti-cancer agents, have shown significant activity against Leishmania spp. and Trypanosoma cruzi, both in vitro and in vivo. Miltefosine, used as a topical formulation (Miltex.)for metastases, was registered in 2002 for the oral treatment of visceral leishmaniasis. LPAs interfere with lipid synthesis in T. cruzi and cancer cells, but the activity is about >20- fold higher against the parasite.
There are no comments on this title.
Log in to your account to post a comment.
